tranexamic acid and Heart Diseases studies

Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.

Research Excerpts

Excerpt	Relevance	Reference
"We describe the case of a bleeding trauma patient who received tranexamic acid (TXA) during air transport who subsequently developed multiple intra-cardiac thrombi."	7.88	Left atrial thrombi following tranexamic acid in a bleeding trauma patient-A word of caution. ( Carroll, ND; Eastridge, BJ; Restrepo, CS; Stasik, CN, 2018)
"We describe the case of a bleeding trauma patient who received tranexamic acid (TXA) during air transport who subsequently developed multiple intra-cardiac thrombi."	3.88	Left atrial thrombi following tranexamic acid in a bleeding trauma patient-A word of caution. ( Carroll, ND; Eastridge, BJ; Restrepo, CS; Stasik, CN, 2018)
"Tranexamic acid is a drug used during open cardiac surgery to prevent blood loss."	3.01	Analysis of serum tranexamic acid in patients undergoing open heart surgery. ( Gauthier, J; Ivica, J; Lamy, A; Potter, M; Power, P, 2021)
" To date, the most efficacious dosing protocol in this setting has not yet been ascertained."	1.72	No Difference in Blood Loss and Risk of Transfusion Between Patients Treated with One or Two Doses of Intravenous Tranexamic Acid After Simultaneous Bilateral TKA. ( Bugbee, WD; Copp, SN; Evans, AS; Ezzet, KA; McCauley, JC; Rosen, AS; Walker, RH; Wilde, JM, 2022)
"Excessive bleeding is a risk associated with cardiac surgery."	1.42	Protocol guided bleeding management improves cardiac surgery patient outcomes. ( Drake, L; Faulke, D; Fraser, JF; Fung, YL; Pearse, BL; Rapchuk, IL; Ryan, EG; Smith, I; Tesar, P; Wall, D; Ziegenfuss, M, 2015)
" Future tranexamic acid trials should assess the blood-conserving effect of tranexamic acid at a lower dosage and specifically monitor for seizure occurrence."	1.38	High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. ( Dagenais, F; Dionne, S; Kalavrouziotis, D; Mohammadi, S; Voisine, P, 2012)

Research

Studies (11)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Estimated Blood Loss

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (9.09)	18.2507
2000's	1 (9.09)	29.6817
2010's	7 (63.64)	24.3611
2020's	2 (18.18)	2.80

Authors	Studies
Wilde, JM	1
Copp, SN	1
Ezzet, KA	1
Rosen, AS	1
Walker, RH	1
McCauley, JC	1
Evans, AS	1
Bugbee, WD	1
Ivica, J	1
Gauthier, J	1
Power, P	1
Lamy, A	1
Potter, M	1
Carroll, ND	1
Restrepo, CS	1
Eastridge, BJ	1
Stasik, CN	1
Schwameis, M	1
Thaler, J	1
Schober, A	1
Schörgenhofer, C	1
Kulinna-Cosentini, C	1
Laggner, A	1
Röggla, M	1
Jilma, B	1
Pearse, BL	1
Smith, I	1
Faulke, D	1
Wall, D	1
Fraser, JF	1
Ryan, EG	1
Drake, L	1
Rapchuk, IL	1
Tesar, P	1
Ziegenfuss, M	1
Fung, YL	1
Gerstein, NS	1
Brierley, JK	1
Culling, MD	1
Kalavrouziotis, D	1
Voisine, P	1
Mohammadi, S	1
Dionne, S	1
Dagenais, F	1
Ferraris, VA	1
Akay, MH	1
Senay, S	1
Karabulut, H	1
Toraman, F	1
Kocyiğit, M	1
Alhan, HC	1
Vanek, T	1
Jares, M	1
Fajt, R	1
Straka, Z	1
Jirasek, K	1
Kolesar, M	1
Brucek, P	1
Maly, M	1
Penta de Peppo, A	1
Pierri, MD	1
Scafuri, A	1
De Paulis, R	1
Colantuono, G	1
Caprara, E	1
Tomai, F	1
Chiariello, L	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Point-of-care (POC) Approach to Management of Coagulopathy in Lung Transplantation Versus Standard Approach and Their Effect on Primary Graft Dysfunction (PGD), Randomized Controlled Study[NCT03598907]		67 participants (Actual)	Observational	2018-01-01	Terminated (stopped due to After interim statistical analysis, a statistician reccommended to stop study, because results are significant and in favour of POC approach.)
The Effect of Tranexamic Acid on Blood Loss and Transfusion Rates in Major Oncologic Surgery[NCT01980355]		76 participants (Actual)	Interventional	2012-06-12	Completed
DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061]	Phase 4	97 participants (Actual)	Interventional	2017-12-21	Completed
Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study[NCT03954314]	Phase 3	3,242 participants (Actual)	Interventional	2019-09-17	Terminated (stopped due to Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Surgical blood loss estimation (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge

Number of Participants Who Required Transfusion

Intervention	mL (Median)
Tranexamic Acid	450
Placebo	365

To determine the impact of perioperative administration of tranexamic acid on blood loss and transfusion rates in major oncologic surgery (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge

Mean Concentration of TxA in Plasma Collected From Participants

Intervention	Participants (Count of Participants)
Tranexamic Acid	8
Placebo	5

Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours

Median Number of Hours Participants Spent in ICU

Intervention	microgram per milliliter per kilogram (Mean)
Topical TxA (Intervention)	0.58
Intravenous TxA (Control)	1.10

Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).

Median Volume of Mediastinal Fluid Collected From Participants

Intervention	hours (Median)
Topical TxA (Intervention)	23
Intravenous TxA (Control)	26

Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure

Number of Participants With Mortality

Intervention	mL (Median)
Topical TxA (Intervention)	500
Intravenous TxA (Control)	540

The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge

Number of Participants With RBC Transfusion

Intervention	Participants (Count of Participants)
Topical TxA (Intervention)	1
Intravenous TxA (Control)	1

Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions

Number of Participants With Re-operation for Bleeding or Tamponade

Intervention	Participants (Count of Participants)
Topical TxA (Intervention)	19
Intravenous TxA (Control)	23

Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge

Number of Participants With Seizures

Intervention	Participants (Count of Participants)
Topical TxA (Intervention)	0
Intravenous TxA (Control)	1

Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge

Article	Year
Analysis of serum tranexamic acid in patients undergoing open heart surgery. Clinical biochemistry, 2021, Volume: 87 Topics: Calibration; Cardiac Surgical Procedures; Chromatography, Liquid; Heart Diseases; Humans; Limit of D	2021
Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2005, Volume: 28, Issue:4 Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery Bypass, Off-Pump; Cr	2005
Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Texas Heart Institute journal, 1995, Volume: 22, Issue:3 Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Tests; Blood L	1995

Article	Year
No Difference in Blood Loss and Risk of Transfusion Between Patients Treated with One or Two Doses of Intravenous Tranexamic Acid After Simultaneous Bilateral TKA. Clinical orthopaedics and related research, 2022, 04-01, Volume: 480, Issue:4 Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L	2022
Left atrial thrombi following tranexamic acid in a bleeding trauma patient-A word of caution. Journal of cardiac surgery, 2018, Volume: 33, Issue:2 Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Female; Heart Atria; Heart Diseases; Hemorrhage; Hep	2018
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings. Thrombosis and haemostasis, 2014, Volume: 112, Issue:5 Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol	2014
Protocol guided bleeding management improves cardiac surgery patient outcomes. Vox sanguinis, 2015, Volume: 109, Issue:3 Topics: Aged; Blood Coagulation Tests; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Erythrocyte Tran	2015
Left ventricle thrombus after tranexamic acid for spine surgery in an HIV-positive patient. The spine journal : official journal of the North American Spine Society, 2016, Volume: 16, Issue:2 Topics: Aged; Antifibrinolytic Agents; Heart Diseases; Heart Ventricles; HIV Infections; Humans; Male; Neuro	2016
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. The Annals of thoracic surgery, 2012, Volume: 93, Issue:1 Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence	2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. The Annals of thoracic surgery, 2012, Volume: 93, Issue:1 Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence	2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. The Annals of thoracic surgery, 2012, Volume: 93, Issue:1 Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence	2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. The Annals of thoracic surgery, 2012, Volume: 93, Issue:1 Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence	2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. The Annals of thoracic surgery, 2012, Volume: 93, Issue:1 Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence	2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. The Annals of thoracic surgery, 2012, Volume: 93, Issue:1 Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence	2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. The Annals of thoracic surgery, 2012, Volume: 93, Issue:1 Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence	2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. The Annals of thoracic surgery, 2012, Volume: 93, Issue:1 Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence	2012
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. The Annals of thoracic surgery, 2012, Volume: 93, Issue:1 Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence	2012
Invited commentary. The Annals of thoracic surgery, 2012, Volume: 93, Issue:1 Topics: Cardiopulmonary Bypass; Female; Heart Diseases; Humans; Male; Seizures; Tranexamic Acid	2012
Low-dose tranexamic acid use in isolated coronary artery bypass surgery. The Annals of thoracic surgery, 2012, Volume: 94, Issue:3 Topics: Cardiopulmonary Bypass; Female; Heart Diseases; Humans; Male; Seizures; Tranexamic Acid	2012

tranexamic acid and Heart Diseases